SLC5A2 and Myocardial fibrosis: Since SGLT2 is mainly expressed in kidneys, but not in cardiomyocytes or cardiac fibroblasts (32), SGLT2 inhibitors may reduce myocardial fibrosis by pleiotropic effects.